MRNS Marinus Pharmaceuticals, Inc.

1.37
+0.21  (18.1%)
Previous Close 1.16
Open 1.40
Price To book 0.86
Market Cap 27.00M
Shares 19,705,000
Volume 27,070,779
Short Ratio 0.96
Av. Daily Volume 916,450

SEC filingsSee all SEC filings

  1. 8-K - Current report 17536627
  2. 8-K - Current report 17515687
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 162012514
  4. 8-K - Current report 162010364
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981716

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 trial to commence in 1H 2017 with data due in 2H 2017.
Ganaxolone
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 2 preliminary CDKL5 cohort data released January 23, 2017. Top-line data due mid-2017.
Ganaxolone
PCDH19

Latest News

  1. Why This Seizure Drug Matters So Much for Marinus Pharma
  2. Marinus Anti-Seizure Drug Did Well in Early Trial
  3. Marinus Pharma stock surges 49% on positive mid-stage data for pediatric epilepsy drug
  4. 7:31 am Marinus Pharmaceuticals announces 'positive' prelim data from the initial CDKL5 patients enrolled in its ongoing Phase 2study evaluating ganaxolone as a treatment for orphan, genetic disorders
  5. Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
  6. MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
  7. MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  8. Marinus Provides Business Outlook for 2017
  9. Marinus Provides Business Outlook for 2017
  10. Main Line biopharm firm gets a boost from the FDA
  11. Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
  12. Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
  13. MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  14. MARINUS PHARMACEUTICALS INC Financials
  15. 5 Stocks Under $10 Poised for Big Breakouts
  16. Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus
  17. MARINUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
  18. Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results
  19. Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results
  20. MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

SEC Filings

  1. 8-K - Current report 17536627
  2. 8-K - Current report 17515687
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 162012514
  4. 8-K - Current report 162010364
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981716
  6. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 161948578
  7. 8-K - Current report 161947162
  8. 8-K - Current report 161914357
  9. 8-K - Current report 161873513
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 161844427